IL17A and psoriasis: Furthermore, another experimental study indicated that FZHFZY inhibited proliferation and improved epidermal differentiation in IL-17A/IL-22/IFN-γ/TNF-α-induced HaCaT cells, as well as the formular could regulate epidermal differentiation and inhibit phosphorylation of the Akt/mTORC1/S6K1 pathway in the skin of mice with imiquimod-induced psoriasis [68].